PeptideCompareN-Acetyl Selank — EU research guide.
N-Acetyl Selank is an acetylated analogue of Selank (TBCE-Lys-Glu-Asp-Gly) with proposed enhanced bioavailability and more pronounced anxiolytic-nootropic effects compared to the parent compound.
What is N-Acetyl Selank?
N-Acetyl Selank modifies the parent Selank molecule with an acetyl group on the N-terminus, increasing lipophilicity and proposed membrane permeability. The mechanism of action mirrors Selank — modulation of GABAergic transmission, BDNF upregulation and IL-6 normalisation — but with claimed enhanced potency per dose.
What does the research show?
Research on N-Acetyl Selank is primarily preclinical and limited compared to the parent Selank, which has more established Russian clinical data. Animal studies suggest comparable or enhanced anxiolytic effects with potentially lower effective dose. Head-to-head human comparisons are absent from published literature.
EU legal status
Not approved anywhere. Available from EU research vendors as a laboratory compound. Same regulatory considerations apply as for Selank.
Molecular information
Pharmacokinetics
Potency retained over time
Each line is one storage condition: it starts at 100% and falls as potency is lost. Above the dashed 80% line the material is considered reliable — hover for exact values.
⚠ Estimates modelled per compound from its molecular properties (sequence length, cyclisation, oxidation- and deamidation-prone residues, light sensitivity). Indicative only — not lab-measured per batch.
N-Acetyl Selank across EU suppliers
COA-verified EU vendors · Updated monthly